2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
Key Takeaways
- Sublocade utilizes the ATRIGEL delivery system (PLGA polymer in N-methyl-2-pyrrolidone) injected strictly subcutaneously into the abdomen, where it solidifies into a biodegradable depot upon contact with interstitial fluid.
- Sublocade requires a minimum of 7 days of transmucosal buprenorphine stabilization (8–24 mg/day) and an initiation regimen of two consecutive monthly 300 mg loading doses followed by 100 mg monthly maintenance.
- Brixadi employs FluidCrystal lipid technology, offering both weekly (8–32 mg) and monthly (64–128 mg) subcutaneous dosing across multiple anatomical sites without mandatory cold storage.
- Extended-release naltrexone (Vivitrol, 380 mg gluteal IM every 4 weeks) demands a strict 7- to 10-day opioid-free window (14 days for methadone/buprenorphine) verified by negative urine toxicology and a naloxone challenge test.
- Vivitrol carries a critical post-treatment loss-of-tolerance warning; patients who relapse to prior opioid doses face an extreme risk of fatal respiratory depression.
2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
Core Clinical Competency: The APRN must evaluate clinical candidacy, navigate complex delivery system pharmacokinetics, execute safe injection protocols, and manage treatment transitions for long-acting injectable (LAI) buprenorphine formulations and extended-release naltrexone to optimize long-term recovery and mitigate overdose mortality.
1. Sublocade (Extended-Release Subcutaneous Buprenorphine)
Sublocade is a monthly subcutaneous injectable buprenorphine formulation designed to eliminate the daily adherence burden and plasma level fluctuations associated with sublingual dosing.
The ATRIGEL Delivery System & Depot Kinetics
- Composition: Sublocade utilizes the proprietary ATRIGEL delivery system, comprising a biodegradable copolymer of poly(DL-lactide-co-glycolide) (PLGA, 50:50 ratio) dissolved in a water-miscible, biocompatible organic solvent, $N$-methyl-2-pyrrolidone (NMP).
- Mechanism of Solidification: When injected into subcutaneous adipose tissue, the water-miscible NMP solvent rapidly diffuses into the surrounding interstitial aqueous fluid. This phase inversion causes the PLGA polymer to precipitate and solidify into a distinct, gelatinous-to-firm subcutaneous depot encapsulating the buprenorphine.
- Sustained Zero-Order Release: The depot slowly hydrolyzes via non-enzymatic ester cleavage into endogenous lactic acid and glycolic acid over weeks to months, providing stable, sustained buprenorphine plasma concentrations ($>2\text{ to }3\text{ ng/mL}$) that achieve ≥70% to 80% mu-opioid receptor occupancy.
Clinical Candidacy & Mandatory Run-In Period
- Indication: Treatment of moderate-to-severe Opioid Use Disorder in adult patients.
- Mandatory Stabilization Period: Patients must initiate treatment with a transmucosal buprenorphine-containing product (sublingual film or tablet) and achieve dose stabilization for at least 7 days (typically 8 mg to 24 mg daily) prior to Sublocade administration. This run-in confirms clinical tolerability and rules out hypersensitivity.
Standard Dosing Regimen
- Loading Phase: 300 mg subcutaneous injection once monthly for the first two months (Month 1 and Month 2).
- Rationale for Loading: Two 300 mg doses are required to rapidly attain steady-state therapeutic plasma concentrations ($>2\text{ ng/mL}$) within the first 48 to 72 hours, preventing early craving breakthrough or illicit opioid use.
- Maintenance Phase: 100 mg subcutaneous injection once monthly starting at Month 3.
- Dose Up-Titration: If a patient on 100 mg maintenance exhibits persistent cravings, withdrawal breakthrough, ongoing illicit opioid use, or has a high body mass index (accelerated clearance), the maintenance dose may be increased to 300 mg monthly.
- Injection Interval: Administered every 28 days (minimum window of 26 days between injections).
Sublocade Standard Monthly Dosing Flow:
[Day -7 to Day 0: SL Buprenorphine Stabilization (8-24 mg/d)]
│
▼
[Month 1: Sublocade 300 mg SC (Abdomen)]
│
▼ (Wait 28 days)
[Month 2: Sublocade 300 mg SC (Abdomen)]
│
▼ (Wait 28 days)
[Month 3+: Sublocade 100 mg SC Monthly Maintenance]
*(May increase to 300 mg monthly for persistent cravings)*
Administration Technique & Black Box Warnings
- STRICTLY ABDOMINAL SUBCUTANEOUS INJECTION ONLY: Injected into the subcutaneous tissue of the abdominal wall between the transpyloric and transtubercular planes, rotating between quadrants.
[!CAUTION] BLACK BOX WARNING — RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION: Sublocade must NEVER be administered intravenously or intramuscularly. Intravenous injection causes the ATRIGEL polymer to instantly solidify upon contact with aqueous blood, forming an occlusive intravascular foreign body that causes massive pulmonary embolism, vascular occlusion, catastrophic tissue necrosis, and immediate death.
- REMS Program Distribution: Distributed exclusively through a restricted Risk Evaluation and Mitigation Strategy (REMS) program. Sublocade is shipped directly from a specialty pharmacy to the healthcare facility and must never be dispensed directly to the patient.
- Cold Chain Storage & Equilibration: Must be refrigerated at 2°C to 8°C (36°F to 46°F). Prior to administration, the prefilled syringe must sit at room temperature for at least 15 to 30 minutes to allow the viscous formulation to warm, facilitating injection and reducing injection-site pain.
2. Brixadi (Subcutaneous Buprenorphine with FluidCrystal Technology)
Approved by the FDA in 2023, Brixadi provides significant therapeutic flexibility, offering both weekly and monthly formulations across diverse anatomical injection sites.
The FluidCrystal Drug Delivery Platform
- Biophysical Mechanism: Brixadi utilizes FluidCrystal lipid technology consisting of phosphatidylcholine and soy lysophosphatidylcholine dissolved in ethanol.
- In Situ Nanostructured Gel: Injected as a low-viscosity liquid through a fine 23-gauge needle. Upon contact with aqueous interstitial fluid in subcutaneous tissue, it self-assembles into an inverted hexagonal liquid-crystalline nanostructured gel that traps buprenorphine and releases it at a consistent, controlled rate as the lipid matrix undergoes slow enzymatic biodegradation.
- Room-Temperature Storage: Unlike Sublocade, Brixadi is stored at room temperature (20°C to 25°C) and requires no refrigeration or pre-injection warming, streamlining clinic workflow.
Dosage Forms & Anatomical Administration Sites
Brixadi offers a broad spectrum of prefilled, single-dose glass syringes equipped with an automatic safety needle guard:
| Formulation | Available Strengths | Clinical Conversion from Daily Sublingual Buprenorphine |
|---|---|---|
| Brixadi Weekly | 8 mg, 16 mg, 24 mg, 32 mg | • ≤6 mg/day SL $\rightarrow$ 8 mg weekly<br>• 8–10 mg/day SL $\rightarrow$ 16 mg weekly<br>• 12–16 mg/day SL $\rightarrow$ 24 mg weekly<br>• 18–24 mg/day SL $\rightarrow$ 32 mg weekly (maximum) |
| Brixadi Monthly | 64 mg, 96 mg, 128 mg | • 8–10 mg/day SL $\rightarrow$ 64 mg monthly<br>• 12–16 mg/day SL $\rightarrow$ 96 mg monthly<br>• 18–24 mg/day SL $\rightarrow$ 128 mg monthly (maximum); no monthly strength is offered for SL ≤6 mg/day |
Unique Clinical Advantages of Brixadi
- Diverse Anatomical Injection Sites: In addition to the abdomen, Brixadi is FDA-approved for subcutaneous injection into the buttock, thigh, and upper arm. Rotating across these sites dramatically reduces injection-site reactions and accommodates patients with abdominal scarring or lipodystrophy.
- Direct Weekly Initiation: In buprenorphine-naive patients or those not yet stabilized, Brixadi Weekly can be initiated after a single test dose of sublingual buprenorphine (e.g., 4 mg SL) to verify tolerability, completely eliminating the mandatory 7-day sublingual run-in required by Sublocade.
- Granular Dose Matching: The multiple weekly and monthly dose strengths allow the APRN to match the patient's exact sublingual dose requirement without forcing a generic 300 mg/100 mg transition.
3. Extended-Release Injectable Naltrexone (Vivitrol)
Vivitrol is an extended-release injectable suspension of the pure opioid antagonist naltrexone, approved for both Opioid Use Disorder and Alcohol Use Disorder.
Receptor Mechanism & Delivery Platform
- Pure Opioid Antagonism: Naltrexone binds competitively to mu-opioid receptors with high affinity and zero intrinsic efficacy. It acts as a silent competitive antagonist, completely blocking full and partial agonists from binding.
- Microsphere Matrix: Formulated as 380 mg of naltrexone embedded within biodegradable poly(D,L-lactide-co-glycolide) (PLG) microspheres suspended in an aqueous diluent. Following deep intramuscular injection, microspheres undergo gradual degradation, maintaining therapeutic antagonist levels for 4 weeks.
- Dosing & Administration: 380 mg administered strictly as a deep intramuscular (IM) gluteal injection every 4 weeks (alternating gluteal muscles each month). Must be administered using the customized 1.5-inch or 2.0-inch safety needle provided in the kit. Never administer subcutaneously or intravenously.
Mandatory Opioid-Free Clearance Window
Because naltrexone possesses high mu-affinity and zero intrinsic efficacy, administering Vivitrol in the presence of circulating full or partial agonists triggers catastrophic, violent precipitated withdrawal.
| Opioid Class Previously Used | Mandatory Minimum Opioid-Free Window |
|---|---|
| Short-Acting Opioids (Heroin, IR Oxycodone, Fentanyl, Morphine) | 7 to 10 days absolute abstinence |
| Long-Acting Opioids (Methadone, Buprenorphine, LA Morphine) | 14 days absolute abstinence |
The Naloxone Challenge Test Protocol
Before administering Vivitrol, the APRN must objectively confirm the absence of circulating opioids:
- Urine Toxicology: Confirm a negative instrumented urine drug screen for all opioids, including synthetic fentanyls, buprenorphine, and methadone.
- Naloxone Challenge Administration: Administer 0.4 mg to 0.8 mg naloxone subcutaneously or intravenously (or 0.8 mg IM).
- Clinical Observation (20–30 Minutes): Observe the patient closely for emergent withdrawal signs:
- Objective signs: Pupillary dilation, diaphoresis, piloerection, tachycardia, tremors, yawning.
- Subjective symptoms: Abdominal cramping, nausea, myalgias, acute craving.
- Interpretation: If any withdrawal signs appear, the test is positive—do NOT give Vivitrol; re-evaluate in 24 to 48 hours. If no symptoms occur after 30 minutes, the test is negative.
- Oral Naltrexone Trial (Optional Clinical Pearl): Many clinicians administer an oral naltrexone trial (25 mg to 50 mg PO daily for 1 to 3 days) following a negative naloxone challenge as an added safety step before injecting the 30-day depot.
4. Loss of Tolerance & Hepatic Safety Monitoring
Black Box Warning: Loss of Opioid Tolerance & Fatal Overdose Risk
During Vivitrol treatment, continuous blockade of mu-opioid receptors results in the complete loss of acquired physiological opioid tolerance. Downstream receptor upregulation and cellular re-sensitization restore the patient to an opioid-naive state.
Vivitrol Loss-of-Tolerance Fatality Mechanism:
[Patient on Vivitrol: Mu Receptors 100% Blocked]
│
▼
[Patient Loses Acquired Opioid Tolerance Over 1-3 Months]
│
▼
┌──────────────────┴──────────────────┐
▼ ▼
[Patient Attempts to Override Blockade] [Patient Misses Next Injection / Relapses]
Consumes massive opioid doses to overcome Resumes opioid use at doses previously
receptor antagonism. If opioid outlasts tolerated during active addiction.
antagonist levels -> FATAL OVERDOSE. -> RAPID FATAL RESPIRATORY APNEA.
[!WARNING] Critical Patient Education Point: Patients must be explicitly educated that if they attempt to overcome the Vivitrol receptor blockade by ingesting large quantities of opioids, or if they relapse after missing an injection or discontinuing treatment, they will die from respiratory arrest at doses they previously tolerated.
Hepatic Monitoring & Safety Parameters
- Metabolism: Naltrexone is metabolized primarily via non-cytochrome P450 hepatic enzymes (aldo-keto reductase) into its primary active metabolite, 6-beta-naltrexol.
- Hepatotoxicity Warnings: Early trials with high-dose oral naltrexone (300 mg/day) revealed hepatocellular injury. While Vivitrol at 380 mg monthly rarely causes significant hepatotoxicity, baseline liver function tests (LFTs) are mandatory.
- Clinical Thresholds: Exercise clinical caution if baseline AST or ALT exceeds 3 to 5 times the upper limit of normal (ULN). Vivitrol is strictly contraindicated in patients with acute hepatitis, hepatic decompensation, or end-stage liver disease.
5. Comparative Matrix: Long-Acting Injectables in Addictions Practice
| Parameter | Sublocade | Brixadi (Monthly) | Vivitrol |
|---|---|---|---|
| Active Molecule | Buprenorphine | Buprenorphine | Naltrexone |
| Pharmacological Class | Mu Partial Agonist | Mu Partial Agonist | Pure Mu Antagonist |
| Delivery Technology | ATRIGEL (PLGA in NMP) | FluidCrystal (Lipid-based) | PLG Microsphere Suspension |
| Route & Site | SC only: Abdomen strictly | SC: Abdomen, thigh, arm, buttock | IM only: Gluteal strictly |
| Pre-Induction Run-In | ≥7 days transmucosal bup | None (or single test dose for weekly) | 7–10 days opioid-free (14d methadone) |
| Needle Gauge / Size | 19G or 20G, 5/8-inch | 23G, 1/2-inch | 20G, 1.5-inch or 2.0-inch |
| Storage Requirement | Refrigerated (2°C–8°C); warm 15–30m | Room temperature (20°C–25°C) | Refrigerated (2°C–8°C); warm to room temp |
| Overdose Risk on Relapse | Low (protective ceiling effect) | Low (protective ceiling effect) | EXTREMELY HIGH (loss of tolerance) |
| Dual AUD/OUD Indication | OUD only | OUD only | Both AUD and OUD |
6. Clinical Decision Algorithm: Selecting LAI Formulations
Clinical Algorithm for Long-Acting Injectable Selection:
[Patient with Moderate-to-Severe OUD]
│
┌───────────────────────────┴───────────────────────────┐
▼ ▼
[Patient Desires Opioid Agonist] [Patient Highly Motivated for
(Suppresses cravings/withdrawal) Total Opioid Abstinence]
│ (e.g., licensed professionals,
│ criminal justice mandate, co-occurring AUD)
▼ │
[Assess Prior Buprenorphine Tolerability] ▼
│ [Extended-Release Naltrexone]
┌────┴────────────────────────┐ • Must be opioid-free 7-10 days
▼ ▼ • Negative UDT + Naloxone challenge
[Stabilized on SL Bup ≥7 days] [Bup-Naive / Immediate Transition] • Administer Vivitrol 380 mg IM gluteal
│ │ • Extensive loss-of-tolerance warning
├─────────────────────────────┘
▼
[Choose Sublocade vs. Brixadi]:
• Sublocade: 300 mg monthly x 2, then 100 mg monthly (Abdominal SC only; cold-chain storage)
• Brixadi: Weekly (8-32 mg) or Monthly (64-128 mg) across Abdomen, Arm, Thigh, Buttock
(Room-temperature storage, smaller injection volume, flexible dosing)
A 31-year-old male with severe opioid use disorder has been successfully stabilized on sublingual buprenorphine/naloxone 16 mg/day for the past 3 weeks with negative urine toxicology. He expresses a desire to transition to monthly Sublocade to eliminate the inconvenience of daily dosing. Which dosing schedule and administration route are FDA-approved and clinically indicated?
An addictions APRN is consulting at a community health center that has limited refrigeration space and treats patients who have severe abdominal scarring from prior surgeries. The clinic wishes to adopt a long-acting buprenorphine formulation that can be stored at room temperature, injected into multiple anatomical sites, and offers both weekly and monthly dosing. Which formulation matches these clinical criteria?
A 39-year-old female with co-occurring severe alcohol use disorder and opioid use disorder presents requesting initiation of extended-release naltrexone (Vivitrol) injections. She states that her last use of illicit fentanyl was 4 days ago. Her urine toxicology screen is positive for fentanyl and norfentanyl. What is the most appropriate advanced practice action?
A patient stabilized on extended-release naltrexone (Vivitrol) 380 mg monthly misses their scheduled appointment at Month 4 and calls the clinic 2 weeks later inquiring about stopping treatment. What critical safety warning regarding the loss of opioid tolerance must the APRN deliver to the patient?